Eilean Therapeutics
🇺🇸United States
Clinical Trials
6
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: ZE50-0134 or placebo
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT06787131
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Randwick NSW, Australia
Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: ZE63-0302 or placebo
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT06780124
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Perth, Nedlands, Australia
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Phase 1
Not yet recruiting
- Conditions
- CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 66
- Registration Number
- NCT06708897
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- AML
- Interventions
- Drug: ZE46-0134 or placeboDrug: Rabeprazole, 20mg oral
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT06399315
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Perth, Nedlands, Australia
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Eilean Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06366789
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Perth, Nedlands, WA, Australia
News
No news found